Autoimmune Thyroiditis in Patients With Diabetes Mellitus: Retrospective Study of 91 Cases.
| Autor: | Hanafi A; Central Laboratory of Biochemistry, Faculty of Medicine and Pharmacy, Ibn Sina University Hospital, Mohammed V University, Rabat, MAR., Lakhlili W; Pharmacy Inspection and Sector Monitoring Department, Directorate of Medicine and Pharmacy (DMP) Ministry of Health and Social Protection, Rabat, MAR., Bouabdellah M; Central Laboratory of Biochemistry, Faculty of Medicine and Pharmacy, Ibn Sina University Hospital, Mohammed V University, Rabat, MAR., Benchekroun L; Central Laboratory of Biochemistry, Faculty of Medicine and Pharmacy, Ibn Sina University Hospital, Mohammed V University, Rabat, MAR. |
|---|---|
| Jazyk: | angličtina |
| Zdroj: | Cureus [Cureus] 2024 Jul 04; Vol. 16 (7), pp. e63805. Date of Electronic Publication: 2024 Jul 04 (Print Publication: 2024). |
| DOI: | 10.7759/cureus.63805 |
| Abstrakt: | Background Detection and quantification of anti-thyroid antibodies make it possible to confirm the diagnosis of thyroid dysfunction as well as its autoimmune origin and monitor thyroid damage in diabetic patients. The aim of this study is to determine the seroprevalence of anti-thyroid antibodies in hospitalized diabetic patients. Materials and methods This retrospective study focused on 91 diabetic patients hospitalized in the endocrinology department of Ibn Sina Hospital, Rabat, Morocco, between January 1 and December 31, 2022. The study population was divided into two groups: 19 patients with type 1 diabetes (13 females and six males, with an age range of 20-70 years) and 72 patients with type 2 diabetes (52 females and 20 males, with an age range of 40-71 years). Hemoglobin (HbA1c) levels were determined with high-performance liquid chromatography (Hb-HPLC) analyzer from blood samples collected in EDTA tubes, and anti-thyroid antibodies (anti-TPO and/or anti-TG) were measured by chemiluminescent microparticle immunoassays (CMIA) in human serum using the ALINITY analyzer. Results Among type 1 diabetic patients, 42.1% (n = 8) were positive for anti-TPO and anti-TG antibodies, while 31.5% (n = 6) were positive only for anti-TPO antibodies. Among type 2 diabetic patients, 15.2% (n = 11) were positive only for anti-TPO antibodies, while 20.8% (n = 15) were positive for anti-TPO and/or anti-TG antibodies. The prevalence of anti-thyroid antibodies was higher in females, consistent with other studies. This could be linked to the involvement of autoimmune processes in the development of thyroid dysfunction in type 2 diabetics. Conclusions Testing for anti-thyroid antibodies in diabetic patients and their relatives helps detect subclinical conditions, which could later manifest as biological and clinical deficiencies, guiding monitoring parameters. Competing Interests: Human subjects: Consent was obtained or waived by all participants in this study. Animal subjects: All authors have confirmed that this study did not involve animal subjects or tissue. Conflicts of interest: In compliance with the ICMJE uniform disclosure form, all authors declare the following: Payment/services info: All authors have declared that no financial support was received from any organization for the submitted work. Financial relationships: All authors have declared that they have no financial relationships at present or within the previous three years with any organizations that might have an interest in the submitted work. Other relationships: All authors have declared that there are no other relationships or activities that could appear to have influenced the submitted work. (Copyright © 2024, Hanafi et al.) |
| Databáze: | MEDLINE |
| Externí odkaz: |
|